Table 3.
Summary of tumor therapies based on the kinases which regulate the crosstalk between phosphorylation and ubiquitination.
| Substrate | Kinase | Inhibitor/activator | Cancer | Ref. |
|---|---|---|---|---|
| SPOP | CDK4/6 | Palbociclib | Colon cancer | 24 |
| c-Fos | EGF | Dihydrocapsaicin | Neoplastic cell transformation | 89 |
| c-Fos | EGF | R1881 | Prostate cancer | 90 |
| PYGO2 | AKT | TCN | Various cancers | 45 |
| BCL2 | PKM2 | PKM2 389–405 peptide | Glioma | 91 |
| BCL2 | PKM2 | Benserazide | Melanoma | 92 |
| BCL2 | PKM2 | Shikonin | Various cancers | 93 |
| ERG | CKI | Etoposide | Prostate cancer | 39 |
| FBW7 | ERK | SCH772984 | Liver cancer | 94 |
| P62 | PKCδ | Rottlerin | Hepatocellular carcinomas | 97 |
| P62 | PKCδ | Sotrastaurin | Non-small cell lung cancer | 98 |